Healthy men to test copycat cancer drug in Early-Stage trial
NCT ID NCT07495930
First seen Apr 25, 2026 · Last updated May 01, 2026 · Updated 3 times
Summary
This early-stage study tests a new drug called HLX319, which is a copy of an approved cancer medicine (Phesgo®), in 24 healthy Chinese men. The goal is to see how the body processes the new drug compared to the original after a single injection. No treatment benefit is expected; the study focuses on safety and drug levels to guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTH ADULT SUBJECTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui Medical University Second Affiliated Hospital
Hefei, Anhui, 230601, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.